Enanta Pharmaceuticals (ENTA) EBIT Margin (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly EBIT Margin came in at 69.07% in Q1 2026, up 9525.0% YoY from 0.72% in Q1 2025, and down 14.26% on a QoQ basis from 60.45% in Q4 2025.
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) EBIT Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of EBIT Margin data on file, last reported at 69.07% in Q1 2026.
- Quarterly EBIT Margin rose 9525.0% year-over-year to 69.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 87.24% (up 7116.0% YoY) and the FY2025 annual result came in at 130.65%, up 4927.0% from the prior year.
- EBIT Margin retreated to 69.07% in Q1 2026, from 60.45% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 60.45% in Q4 2025 to a low of 221.7% in Q1 2023.
- A 5-year average of 151.2% and a median of 163.9% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin tumbled 6652 bps — and 2026, when it surged 9525 bps.
- Tracing ENTA's EBIT Margin over 5 years: stood at 127.25% in 2022, then slumped by 52 bps to 193.78% in 2023, then rose by 28 bps to 138.82% in 2024, then jumped by 56 bps to 60.45% in 2025, then slipped by 14 bps to 69.07% in 2026.
- The last three EBIT Margin figures came in at 69.07% (Q1 2026), 60.45% (Q4 2025), and 121.56% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Enanta Pharmaceuticals | 409.30 Mn | 219.79 Mn | - | -120.04% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -120.04% |
| Mar 31, 2026 | -69.07% |
| Dec 31, 2025 | -60.45% |
| Sep 30, 2025 | -121.56% |
| Jun 30, 2025 | -103.16% |
| Mar 31, 2025 | -164.32% |
| Dec 31, 2024 | -138.82% |
| Sep 30, 2024 | -204.38% |
| Jun 30, 2024 | -134.58% |
| Mar 31, 2024 | -192.13% |
| Dec 31, 2023 | -193.78% |
| Sep 30, 2023 | -163.90% |
| Jun 30, 2023 | -194.33% |
| Mar 31, 2023 | -221.70% |
| Dec 31, 2022 | -127.25% |
| Sep 30, 2022 | -133.13% |
| Jun 30, 2022 | -167.05% |
| Mar 31, 2022 | -180.85% |
| Dec 31, 2021 | -109.99% |
| Sep 30, 2021 | -143.06% |